CPCarmen Petitjean

Carmen Petitjean

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carmen Petitjean has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Alexia Sampri

    British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge , Papworth Road, Cambridge CB2 0BB

    1 shared publication
  • Andrew W. Dangel

    Department of Microbial Infection and Immunity, The Ohio State University, Columbus, USA

    1 shared publication
  • Angela M. Wood

    Department of Public Health and Primary Care, University of Cambridge , Cambridge

    1 shared publication
  • Ankita Saini

    Department of Microbial Infection and Immunity, The Ohio State University, Columbus, USA

    1 shared publication
  • Anna J Stevenson

    British Heart Foundation Data Science Centre, Health Data Research UK , London

    1 shared publication
  • Antonis C. Antoniou

    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN

    1 shared publication

Latest Publications

  • Open Access

    High-resolution promoter interaction analysis implicates genes involved in activation of type 3 innate lymphoid cells in immune disease risk

    by Valeriya Malysheva, Helen Ray-Jones, Nora Lakes, Rachel A. Brown, Tareian A. Cazares, Owen Clay, David E. Ohayon, Pavel Artemov, Joseph A. Wayman, Zi F. Yang, et al.

    Innate lymphoid cells (ILCs) are rare tissue-resident lymphocytes that functionally mirror cells of CD4 + T helper lineage but lack antigen receptors. Type 3 ILCs (ILC3s) are enriched at barrier sites, regulating inflammation and promoting tissue integrity. Here we profile the promoter-anchored chromosomal contacts of primary human ILC3s using low-input, high-resolution targeted chromosome conformation capture and compare them with those in CD4 + T cells. We use these data to link Crohn’s disease genome-wide association study variants with target genes, implicating both known and unanticipated candidates, including CLN3 , a causal gene for Batten disease. We show that Cln3 overexpression in a mouse ILC3-like cell line alters stimulation-induced transcriptional programs and cytokine secretion. Extending our approach to five additional immune genome-wide association study traits reveals enrichment for regulators of ILC3 activation. Our work develops methods, maps long-range gene regulation in ILC3s, and prioritizes immune disease risk genes with roles in this clinically relevant immune cell type.

  • Open Access

    Using population-wide electronic health records for timely contemporary assessment of cardiovascular disease risk prediction model performance: COVID-19 impact on the SCORE2 models

    by Carmen Petitjean, Spencer J Keene, Thomas Bolton, Alexia Sampri, Genevieve Cezard, Samantha Ip, Fionna Chalmers, Anna J Stevenson, Stelios Boulitsakis Logothetis, Spiros Denaxas, et al.

    Aims: Risk estimation is key for the primary prevention of cardiovascular diseases (CVD). The European Society of Cardiology recommends SCORE2, SCORE2-OP (Older Persons), and SCORE2-Diabetes [collectively, the SCORE2 family-of-models (FOMs)] for 10-year CVD risk estimation. As the COVID-19 pandemic was associated with higher CVD incidences, we externally validated the SCORE2-FOMs using contemporary nationwide data and assessed the need for adaptation. Methods: Using population-wide electronic health records (EHRs) for England, we defined a cohort of 26.5 million individuals aged 40–89 years without prior CVD on 1 January 2022 followed up until 31 December 2023. We calculated annual incidence rates of CVD events and non-CVD mortality by sex and 1-year age groups to estimate expected 10-year, competing risk adjusted, CVD risk using a life table approach. We assessed SCORE2-FOM calibration and discrimination, overall and by subgroups. Results: Within 2 years of follow-up, 239 815 incident CVD events occurred. For SCORE2, SCORE2-Diabetes, and SCORE2-OP, the C-index values were 0.75 (95% CI: 0.75–0.76), 0.71 (0.71–0.71), and 0.65 (0.65–0.65), respectively. SCORE2-FOMs overpredicted CVD risks by 3%–4% in males and by 8%–14% in females, with calibration variations by English region and ethnic group. Elevated CVD risk associated with a recent COVID-19 hospitalization led SCORE2 to underestimate risks by 2% in affected males aged 40–69 years. Conclusion: The SCORE2-FOMs demonstrated good calibration and discrimination, suggesting that no adaptation is needed in response to the COVID-19 pandemic. Short-term EHRs provide a valuable resource for timely contemporary risk model validation and, if necessary, for adaptation according to shifts in CVD trends.

  • Open Access

    Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank

    by Carmen Petitjean, Naomi Wilcox, Lorenzo Ficorella, Joe Dennis, Jonathan Tyrer, Michael Lush, Jacques Simard, Douglas Easton, Antonis C Antoniou, Xin Yang

    Background: The Breast and Ovarian Analysis of Disease Incidence Algorithm (BOADICEA) model predicts breast cancer risk using cancer family history, epidemiological, and genetic data. We evaluated its validity in a large prospective cohort. Methods: We assessed model calibration, discrimination and risk classification ability in 217 885 women (6838 incident breast cancers) aged 40-70 years of self-reported White ethnicity with no previous cancer from the UK Biobank. Age-specific risk classification was assessed using relative risk thresholds equivalent to the absolute lifetime risk categories of less than 17%, 17%-30%, and 30% or more, recommended by the National Institute for Health and Care Excellence guidelines. We predicted 10-year risks using BOADICEA v.6 considering cancer family history, questionnaire-based risk factors, a 313–single nucleotide polymorphisms polygenic score, and pathogenic variants. Mammographic density data were not available. Results: The polygenic risk score was the most discriminative risk factor (area under the curve [AUC] = 0.65). Discrimination was highest when considering all risk factors (AUC = 0.66). The model was well calibrated overall (expected-to-observed ratio = 0.99, 95% confidence interval [CI] = 0.97 to 1.02; calibration slope = 0.99, 95% CI = 0.99 to 1.00), and in deciles of predicted risks. Discrimination was similar in women aged younger and older than 50 years. There was some underprediction in women aged younger than 50 years (expected-to-observed ratio = 0.89, 95% CI = 0.84 to 0.94; calibration slope = 0.96, 95% CI = 0.94 to 0.97), which was explained by the higher breast cancer incidence in UK Biobank than the UK population incidence in this age group. The model classified 87.2%, 11.4%, and 1.4% of women in relative risk categories less than 1.6, 1.6-3.1, and at least 3.1, identifying 25.6% of incident breast cancer patients in category relative risk of at least 1.6. Conclusion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year breast cancer risk, which can facilitate risk-stratified screening and personalized breast cancer risk management.